↑ 疾患リストへ　← 戻る

 40. 高安動脈炎　［臨床試験数：16，薬物数：23（DrugBank：16），標的遺伝子数：16，標的パスウェイ数：94］ 

Searched query = "Takayasu arteritis", "Aortitis syndrome", "Pulseless disease"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03482479February 4, 201922 October 2019Low Dose Naltrexone to Improve Physical Health in Patients With VasculitisLow Dose Naltrexone to Improve Physical Health in Patients With VasculitisEosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arteritis;Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Polyarteritis Nodosa;Takayasu ArteritisDrug: Naltrexone Hydrochloride;Other: Placebo ComparatorUniversity of PennsylvaniaRecruiting18 YearsN/AAll60Phase 2United States
2NCT03550781June 1, 201818 June 2018Anti-inflammatory Treatment for Inactive Takayasu ArteritisDoes Inactive Takayasu Arteritis(NIH Criteria) Need Anti-inflammatory Treatment?Takayasu Arteritis;Anti-Inflammatory AgentsDrug: Prednisone, cyclophosphamideChinese Academy of Medical Sciences, Fuwai HospitalNot recruiting10 Years40 YearsAll40Phase 2/Phase 3
3NCT03430388January 31, 20186 May 2019Yellow Fever Vaccine in Patients With Rheumatic DiseasesEvaluation of Yellow Fever Vaccine in Patients With Rheumatic Diseases Under Low Immunosuppression Level and Residing in a Risk AreaSystemic Lupus;Rheumatoid Arthritis;Spondyloarthritis;Inflammatory Myopathy;Systemic Sclerosis;Mixed Connective Tissue Disease;Takayasu Arteritis;Granulomatosis With Polyangiitis;Sjogren's Syndrome;Juvenile Idiopathic Arthritis;Juvenile DermatomyositisBiological: Yellow Fever vaccine (17D)University of Sao Paulo General HospitalNot recruiting2 Years60 YearsAll600N/ABrazil
4NCT03096275March 16, 201716 December 2017Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's ArteritisComparison of the Efficacy of Mycophenolate Mofetil Combined With Methotrexate and Cyclophosphamide for the Treatment of Takayasu's ArteritisTakayasu ArteritisDrug: MMF;Drug: CYC;Drug: Glucocorticoids;Drug: MTX;Drug: AZAChinese SLE Treatment And Research GroupPeking Union Medical College HospitalRecruiting18 YearsN/AAll150Phase 3China
5NCT03192878March 1, 201716 December 2017Infliximab Biosimilar in Takayasu's ArteritisA Prospective Observational Study of Infliximab Biosimilar in the Treatment of Takayasu's Arteritis Resistant to Corticosteroids and Conventional Immune-suppressive TreatmentsTakayasu ArteritisDrug: InfliximabOspedale San RaffaeleRecruiting18 YearsN/AAll30N/AItaly
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6JPRN-UMIN0000259402017/02/072 April 2019Clinical Research on the Safety of anti-interleukin-6 antibody (Tocilizumab) treatment for the refractory patients with Takayasu ArteritisTakayasu arteritisIntravenous administration of
tocilizumab (8mg/kg/month) for up to 12 months		Osaka UniversityNational Cerebral and Cardiovascular CenterNot Recruiting16years-old60years-oldMale and Female2Not selectedJapan
7NCT02981979December 20164 March 2019Takayasu Arteritis Clinical Trial in ChinaComparison of the Efficacy and Safety of Leflunomide Versus Placebo Combine With the Basic Prednisone Therapy in Patients With Active Phase of Takayasu's Arteritis: a Randomized Controlled Double-blinded TrialTakayasu ArteritisDrug: Leflunomide 10mg Tab;Drug: Prednisone Acetate;Drug: PlacebosJiang lindiRecruiting18 Years65 YearsAll116N/AChina
8NCT03893136November 1, 20168 April 2019The Registry Study of Takayasu Arteritis in East ChinaThe Cohort Study of East Chinese Takayasu's Arteritis (ECTA-cohort Study)Takayasu Arteritis;Mechanisms, Defense;Pregnancy Related;Treatment Refusal;OutcomeBiological: Tocilizumab;Drug: LeflunomideShanghai Zhongshan HospitalRecruiting18 Years65 YearsAll1000N/AChina
9NCT02925351January 25, 201611 November 2019Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory DiseasesThe Biodistribution of 18F-Clofarabine in Patients With Autoimmune and Inflammatory DiseasesAutoimmune Disease;Crohn Disease;Inflammatory Disorder;Rheumatoid Arthritis;Systemic Lupus Erythematosus;Takayasu ArteritisProcedure: Computed Tomography;Radiation: Fluorine F 18 Clofarabine;Procedure: Positron Emission TomographyJonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Not recruiting18 YearsN/AAll8N/AUnited States
10NCT02457585March 201516 December 2017Clinical Study of Anti-tumor Necrosis Factor Therapy in Patients With Takayasu ArteritisAnti-tumor Necrosis Factor Therapy Effect on Takayasu ArteritisTakayasu's ArteritisDrug: remicade (anti tumor necrosis factor inhibitor)Seoul National University HospitalRecruiting18 YearsN/AAll11Phase 2Korea, Republic of
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
11JPRN-UMIN0000259432014/08/072 April 2019Long-term Safety of treatment with tocilizumab in the refractory patients with Takayasu ArteritisTakayasu arteritisIntravenous administration of
tocilizumab (8mg/kg/month) will be performed until December 31st, 2017.		Osaka UnversityNational Cerebral and Cardiovascular CenterNot Recruiting16years-old60years-oldMale and Female9Not selectedJapan
12NCT02101333June 10, 201416 December 2017Efficacy and Tolerance of Tocilizumab In Takayasu ArteritisEfficacy and Tolerance of First-line Treatment With Tocilizumab in Active Takayasu Arteritis French Prospective Multicenter StudyTAKAYASU ARTERITISDrug: TocilizumabAssistance Publique - Hôpitaux de ParisChugai PharmaceuticalRecruiting18 Years77 YearsAll15Phase 3France
13JPRN-JapicCTI-14261601/6/20142 April 2019Phase III Study of MRA-SC in Patients with Takayasu ArteritisA Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Study of MRA-SC in Patients with Takayasu ArteritisTakayasu ArteritisIntervention name : tocilizumab (MRA-SC)
Dosage And administration of the intervention : 162mg/W, SC
Control intervention name : Placebo
Dosage And administration of the control intervention : Placebo/W, SC		Chugai Pharmaceutical Co., Ltd.12BOTH34Phase 3
14JPRN-UMIN0000088122012/10/012 April 2019Efficacy and safety of tocilizumab mono-therapy in patients with large vessel vasculitis (LVV; giant cell arteritis or Takayasu arteritis) and polymyalgia rheumatica (PMR)Rheumatoid arthritistocilizumab monotherapyDepartment of Rheumatology & Clinical Immunology Saitama Medical Center, Saitama Medical UniversitityNot Recruiting16years-old80years-oldMale and Female40Not selectedJapan
15JPRN-UMIN0000078452012/05/012 April 2019Efficacy and Safety of treatment with tocilizumab in refractory patients with Takayasu ArteritisTakayasu arteritisIntravenous administration of tocilizumab (8mg/kg/month) for 24 monthsDepartment of Cardiovascular Medicine Graduate School of Medicine Osaka UniversityNot Recruiting16years-old60years-oldMale and Female15Not selectedJapan
No.TrialIDDate_
enrollement		Last_Refreshed_
on		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
16NCT00006055March 200019 February 2015Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune DiseasesPurpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu ArteritisDrug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell TransplantationFairview University Medical CenterNot recruiting1 Year55 YearsBoth10N/AUnited States

先頭へ